S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)(1A) receptors: I. Interaction with cloned human (h)5 HT(1A), dopamine hD2/hD3 and hα(2a)-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 132-147

  Millan, Mark J ^a,c   Newman Tancredi, Adrian ^a   Rivet, Jean Michel ^a   Brocco, Mauricette ^a   Lacroix, Pierre ^b   Audinot, Valérie ^a   Cistarelli, Laetitia ^a   Gobert, Alain ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b Biotrial SA   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,4 BENZODIOXAN 5 YL) 4 (2 INDANYL)PIPERAZINE; ALPHA 2A ADRENERGIC RECEPTOR; ANXIOLYTIC AGENT; AUTORECEPTOR; BRAIN MONOAMINE; DESIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUOXETINE; KETANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SPECIFICITY; DRUG STRUCTURE; ESCAPE BEHAVIOR; FORCED SWIMMING TEST; FRONTAL CORTEX; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNED HELPLESSNESS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DOPAMINE; FLUOXETINE; FRONTAL LOBE; HUMANS; MALE; NOREPINEPHRINE; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN AGONISTS;

EID: 0030855903     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (131)

1. 2-adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res. 630: 271-282, 1993.
2. 2 and β-adrenergic receptor binding sites in the brain of suicide victims. Arch. Gen. Psychiatry 47: 1038-1047, 1990.
3. ARBORELIUS, L., NOMIKOS, G. G., HACKSELL, U. AND SVENSSON, T. H.: (R)-8-OH-DPAT preferentially increases DA release in rat medial prefrontal cortex. Acta Physiol. Scand. 148: 465-466, 1993.
4. 2 receptors in suicide victims. Biol. Psychiatry 35: 457-463, 1994.
5. ARTIGAS, F., PEREZ, V. AND ALVAREZ, E.: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry, 51: 248-251, 1994.
6. 1A antagonists. Trends Neuropharmacol. Sci. 19: 378-383, 1996.
7. ASTON-JONES, G., AKAOKA, H., CHARLÉTY, P. AND CHOUVET, G.: Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J. Neurosci. 11: 760-769, 1991a.
8. ASTON-JONES, G., CHIANG, C. AND ALEXINSKY, T.: Discharge of noradrenergic locus coerulus neurons in behaving rats and monkeys suggests a role in viligance. Prog. Brain Res. 88: 501-520, 1991b.
9. 2 receptors in the "learned helplessness" rat. Eur. J. Pharmacol. 183: 1900-1901, 1990.
10. 2 receptor sensitivity in the rat. Eur. J. Pharmacol. 231: 395-406, 1993.
11. BAXTER, L. R., SCHWARTZ, J.-M., PHELPS, M. E., MAZZIOTA, J. C., GUZE, B. H., SELIN, C. E., GERNER, R. H. AND SUMIDA, R. M.: Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry 46: 243-254., 1989.
12. 2 receptor. Downregulation results in anxiolytic effects in the elevated plus-maze test. Drug Devel. Res. 26: 287-297, 1992.
13. BLIEH, P. AND DE MONTIGNY, C.: Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15: 220-226, 1994.
14. 1B receptors. J. Pharmacol. Exp. Ther. 250: 37-43, 1989.
15. BOLDEN-WATSON, C. AND RICHELSON, E.: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52: 1023-1029, 1993.
16. BORSINI, F. AND MELI, A.: Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94: 147-160, 1988.
17. BRILEY, M. AND MORET, C.: 5-HT and antidepressants: in vitro and in vivo release studies. Trends Pharmacol. Sci. 14: 396-397, 1993.
18. BROEKKAMP, C. L. E., LEYSEN, D., PEETERS, B. W. M. M. AND PINDER, R. M.: Prospects for improved antidepressants. J. Med. Chem. 38: 4615-4633, 1995.
19. 2 receptors and the abundancies of 5-HT receptor and transporter mRNA in the cortex, hippocampus and dorsal raphe of three strains of rat. Brain Res. 638: 311-324, 1994.
20. BYERLEY, W. F., MCCONNELL, E. J., MCCABE, R. T., DAWSON, T. M., GROSSER, B. I. AND WAMSLEY, J. K.: Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology 94: 141-143, 1988.
21. CARBONI, E., TANDA, G., FRAU, R. AND DI CHIARA, G.: Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55: 1067-1070, 1990.
22. CARLSSON, J. N., FITZGERALD, L. W., KELLER, R. W. AND GLICK, S. D.: Lateralized changes in prefrontal cortical dopamine activity induced by controllable and uncontrollable stress in the rat. Brain Res. 630: 178-187, 1993.
23. CENCI, M. A., KALÉN, P., MANDEL, R. J. AND BJÖRKLUND, A.: Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: A microdialysis study in the rat. Brain Res. 581: 217-228, 1992.
24. CERVO, L. AND SAMANIN, R.: Effect of chronic treatment with 8-OH-DPAT in the forced swimming test requires the integrity of presynaptic serotonergic mechanisms. Psychopharmacology 103: 524-528, 1991.
25. CHEN, N. H. AND REITH, E. A.: Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systematically with (±)-8-hydroxy-2-(di-n-propylamino) tetralin. J. Neurochem. 64: 1585-1597, 1995.
26. 1A receptor. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 1301-1310, Raven Press, Ltd, New York, 1995.
27. 2-noradrenergic system. Drug Aging 5: 116-126, 1994.
28. DETKE, M. J., KIRBY, L. AND LUCKI, I.: Serotonergic mechanisms involved in the effects of fluoxetine in the rat forced swimming test (FST). Neurosci. Abstr. 21: 976, 1995.
29. DREVETS, W. C., VIDEEN, T. O., PRICE, J. L., PRESKORN, S. H., CARMICHAEL, S. T. AND RAICHLE, M. E.: A functional anatomical study of unipolar depression. J. Neurosci. 12: 3628-3641, 1992.
30. DRUGAN, R. C., MAIER, S. F., SKOLNICK, P., PAUL, S. M. AND CRAWLEY, J. N.: An anxiogenic benzodiazepine receptor ligand induces learned helplessness. Eur. J. Pharmacol. 113: 453-457, 1985.
31. FABRE, L. F.: Buspirone in the management of major depression: A placebo-controlled comparison. J. Clin. Psychiatry 51: 55-61, 1990.
32. 1A receptor binding sites following chronic treatment with ipsapirone measured by quantitative autoradiography. Synapse 12: 75-81, 1992.
33. FERRON, A.: Modified coeruleo-cortical noradrenergic neurotransmission after serotonin depletion by PCPA: electrophysiological studies in the rat. Synapse 2: 532-536, 1988.
34. 2-adrenoceptors on serotonergic nerve endings in human and rat neocortex. J. Neurochem. 61: 474-480, 1993.
35. FOOTE, S. L. AND ASTON-JONES, G. S.: Pharmacology and physiology of central noradrenergic systems. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 347-354, Raven Press, Ltd, New York, 1995.
36. 1A autoreceptor antagonists restore serotonergic neuronal activity after acute fluoxetine treatment in behaving cats. Am. Soc. Neurosci. 21: 977, 1995.
37. GAMBARANA, C., GHIGLIERI, O., TADDEI, I., TAGLIAMONTE, A. AND DE MONTIS, M. G.: Imipramine and fluoxetine prevent the stress-induced escape deficits in rats through a distinct mechanism of action. Behav. Pharmacol. 6: 66-73, 1995.
38. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115: 1064-1070, 1995.
39. GLENNON, R. A. AND DUKAT, M.: Serotonin receptor subtypes. In Psychopharmacology: The Fourth Generation of Progress., ed. by F. E. Bloom and D. J. Kupfer, pp. 347-354, Raven Press, Ltd, New York, 1995.
40. GOBBI, M., CAVANUS, S., MIARI, A. AND MENNINI, T.: Effect of acute and chronic administration of buspirone on serotonin and benzodiazepine receptor subtypes in the rat brain: an autoradiographic study. Neuropharmacology 30: 313-321, 1991.
41. 1A receptor agonists and antagonists: A comparison to adrenergic and dopaminergic neurons in rats. J. Pharmacol. Exp. Ther. 273: 1032-1046, 1995a.
42. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J. Pharmacol. Exp. Ther. 275: 899-913, 1995b.
43. 3 (auto) receptors inhibits dopamine release in the frontal cortex of freely moving rats in vivo. J. Neurochem. 66: 2209-2212, 1996.
44. 1B receptors with WAY 100,635 and GR 127,935. J. Neurochem. 68: 1159-1163, 1997.
45. 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J. Neurochem. 63: 256-265, 1994.
46. 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J. Neurochem. 62: 2262-2268, 1994.
47. 2 receptors. Eur. J. Pharmacol. 154: 285-291, 1988.
48. GRAEFF, F. G., AUDI, E. A., ALMEIDA, S. S., FRAEFF, E. O. AND HUNZIKER, M. H. L.: Behavioral effects of 5-HT receptor ligands in the aversive brain stimulation, elevated plus-maze and learned helplessness tests. Neurosci. Biobehav. Rev. 14: 501-506, 1990.
49. GRANIER, F., GIRARD, M., SCHMITT, L., BOSCREDON, J., OULES, J. AND ESCANDE, M.: Depression and anxiety: mianserin and nomifensine compared in a double-blind multicentre trial. Acta Psychiatr. Scand. 72: 67-74, 1985.
50. 1A receptor antagonist, WAY 100,635, is dependent on the phase of the light-dark cycle. In Monitoring Molecules in Neuroscience, Proceedings of the 6th International Conference on In Vivo Methods, ed. by A. Louilot, T. Durkin, U. Spampinato and M. Cador, pp. 211-212, Publi ryp, Gradignan, 1994.
51. HAND, T. H., Hu, X. T. AND WANG, R. Y.: Differential effects of acute clozapine and haloperidol on the activity of ventral (A10) and nigrostratal (A9) dopamine neurons. Brain Res. 415: 257-269, 1987.
52. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur. J. Pharmacol. 260: 251-255, 1994.
53. 1A autoreceptors and α-adrenoceptors in the inhibition of 5-HT release-I. BMY 7378 and prazosin. Neuropharmacology 34: 615-620, 1995.
54. 2 receptors in rat brain. An autoradiographic study. Synapse 14: 324-331, 1993.
55. ICHIKAWA, J. AND MELTZER, H. Y.: Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur. J. Pharmacol. 281: 255-261, 1995.
56. INVERNIZZI, R., BELLI, S. AND SAMANIN, R.: Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584: 322-324, 1992.
57. 1A receptors. Eur. J. Pharmacol. 260: 243-246, 1994.
58. JORDAN, S., KRAMER, G. L., ZUKAS, P. K., MOELLER, M. AND PETTY, F.: In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18: 294-297, 1994.
59. KAROUM, F., EGAN, M. F. AND WYATT, R. J.: Selective reduction in dopamine turnover in the rat frontal cortex and hypothalamus during withdrawal from repeated cocaine exposure. Eur. J. Pharmacol. 254: 127-132, 1994.
60. KAWAHARA, H., YOSHIDA, M., YOKOO, H., NISHI, M. AND TANAKA, M.: Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci. Lett. 162: 81-84, 1993.
61. KITAYAMA, I., NAKAMURA, S., YAGA, T., MURASE, S., NOMURA, J., KAYAHARA, T. AND NAKANO, K.: Degeneration of locus coeruleus axons in stress-induced depression model. Brain Res. Bull. 35: 573-580, 1994.
62. 3 receptor binding affinities. Eur. J. Pharmacol. 277: 209-214, 1995.
63. 1A receptors in vivo. Eur. J. Pharmacol. 240: 307-310, 1993.
64. 3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur. J. Pharmacol. 275: R7-R9, 1995.
65. 1A autoreceptors enhances dopamine (DA) and noradrenaline (NAD) release in rat frontal cortex: influence of S 15535, WAY 100,635 and 8-OH-DPAT. Eur. Neuropsychopharmacol. 6: S4.121-S4.122, 1996.
66. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in the rat. J. Pharmacol. Exp. Ther. 280:1241-1249, 1997.
67. LUCKI, I., SINGH, A. AND KREISS, D. S.: Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci. Biobehav. Rev. 18: 85-95, 1994.
68. MAES, M. AND MELTZER, H. Y.: The serotonin hypothesis of major depression. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 347-354, Raven Press, Ltd, New York, 1995.
69. 2 antagonists have antidepressant-like effects on differential-reinforcement-of-low-rate 72-second schedule. J. Pharmacol. Exp. Ther. 250: 52-59, 1989.
70. 1A agonist, in the learned helplessness paradigm: Evidence for a postsynaptic mechanism. Behav. Br. Res. 38:135-144, 1990a.
71. MARTIN, P., SOUBRIÉ, P. AND PUECH, A. J.: Reversal of helpless behavior by serotonin uptake blockers in rats. Psychopharmacology 101: 403-407, 1990b.
72. 1A post-synaptic receptors in the learned helplessness paradigm. Life Sci. 48: 2505-2511, 1991.
73. 1A receptor activation in mice. Eur. J. Pharmacol. 280: 235-238, 1995.
74. MELTZER, H. Y.: Atypical antipsychotic drugs. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 1277-1286, Raven Press, Ltd, New York, 1995.
75. 2 receptor function as measured by serotonin-stimulated phosphoinositide hydrolysis in platelets of depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 15: 49-61, 1991.
76. 1c/2 antagonists as therapeutic agents. Drug News Perspect. 5: 397-406, 1992.
77. A-adrenergic receptors in the control of nociception, motor behaviour and hippocampal synthesis of noradrenaline. J. Pharmacol. Exp. Ther. 270: 958-972, 1994a.
78. 1A antagonists. J. Pharmacol. Exp. Ther. 268: 337-352, 1994b.
79. 3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: I. Activation of postsynaptic D3 receptors mediates hypothermia while blockade of D2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 275: 885-898, 1995.
80. MOGHADDAM, B. AND BUNNEY, B. S.: Differential effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54: 1755-1760, 1990.
81. 1A antagonists WAY 100,135 and WAY 100,635, on guinea-pig behaviour and dorsal raphe 5-HT neurone firing. Br. J. Pharmacol. 117: 750-756, 1996.
82. NAKAMURA, S.: Antidepressants induce regeneration of catecholaminergic axon terminals in the rat cerebral cortex. Neurosci. Lett. 111: 64-68, 1990.
83. 2 receptor-mediated behavior 11 days after shock in learned helplessness rats. Eur. J. Pharmacol. 281: 123-130, 1995.
84. 2-adrenoceptors in rat brain. Life Sci. 47: 1683-1691, 1990.
85. 1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells. Biochem. J. 285: 933-938, 1992.
86. 1A receptors. Eur. J. Pharmacol. 307: 107-111, 1996a.
87. 3H]CGP-12177 binding reveals rapid (24 hour) modulation. Brain Res. Bull. 40: 93-96, 1996b.
88. OKADA, F. AND TOKUMITSU, Y.: Is the β-down-regulation a prerequisite of the antidepressant activity? J. Psychopharmacol. 8: 62-63, 1994.
89. 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J. Neurochem. 63: 617-624, 1994.
90. OZAWA, H., KATAMURA, Y., HATTA, S., AMEMIYA, N., SAITO, T., OHSHIKA, H. AND TAKAHATA, N.: Antidepressants directly influence in situ binding of guanine nucleotide in synaptic membrane. Life Sci. 54: 925-932, 1994.
91. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney, Australia, 1986.
92. 1A receptors. Am. Soc. Neurosci. 21: 1855, 1995.
93. 3H] spiroperidol by chronic treatment with the antidepressant amitriptyline. J. Pharmacol. Exp. Ther. 215: 582-587, 1980.
94. PESSIA, M., JIANG, Z. G., NORTH, R. A. AND JOHNSON, S. W.: Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res. 654: 324-330, 1994.
95. PETTY, F. AND SHERMAN, A. D.: Learned helplessness induction decreases in vivo cortical serotonin release. Pharmacol. Biochem. Behav. 18: 649-650, 1983.
96. 11C]WAY-100635. Eur. J. Pharmacol. 283: R1-R3, 1995.
97. POLLACK, M. H. AND HAMMERNESS, P.: Adjunctive yohimbine for treatment in refractory depression. Biol. Psychiatry 33: 220-221, 1993.
98. PORSOLT, R. D., ANTON G., BLAVET, N. AND JALFRE, M.: Behavioral despair in rats, a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47: 379-391, 1979.
99. PRISCO, S. AND ESPOSITO, E.: Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmacol. 116: 1923-1931, 1995.
100. REDFERN, W. S., MACKINNON, A. C., BROWN, C. M., MARTIN, A. B., KILPATRICK, A. T., CLAGUE, R. U. AND SPEDDING, M.: Modulation of central noradrenergic function by RS-15385-197. Br. J. Pharmacol. 108: 526-533, 1993.
101. RIVA, M. A. AND CREESE, I.: Reevaluation of the regulation of β-adrenergic receptor binding by desipramine treatment. Mol. Pharmacol. 36: 211-218, 1989.
102. ROBBINS, T. W. AND EVERITT, B. J.: Central norepinephrine neurons and behavior. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 363-372, Raven Press, Ltd, New York, 1995.
103. 2 receptor mRNA levels. Eur. J. Pharmacol. 207: 169-172, 1991.
104. ROTH, B. L. AND MELTZER, H. Y.: The role of serotonin in schizophrenia. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 1215-1228, Raven Press, Ltd, New York, 1995.
105. SACHDEV, P. AND ANISS, A. M.: Slowness of movement in melancholic depression. Biol. Psychiatry 35: 253-262, 1994.
106. 2-adrenoceptor antagonists idazoxan and yohimbine increase rates of DRL responding in rats. Psychopharmacology 95: 413-417, 1988.
107. SAWAGUCHI, T., MATSUMURA, M. AND KUBOTA, K.: Dopamine enhances the neuronal activity of spatial short-term memory task in the primate prefrontal cortex. J. Neurophysiol. 63: 1401-1412, 1990.
108. SCHECHTER, L. E., BOLAÑOS, F. J., GOZLAN H., LANFUMEY, L., HAJ-DAHMANE, S., LAPORTE, A.-M., FATTACCINI, C.-M. AND HAMON, M.: Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsaspirone: biochemical and electrophysiological studies. J. Pharmacol. Exp. Ther. 255: 1335-1345, 1990.
109. 1A receptor agonists 8-OH-DPAT and ipsapirone in the rat forced swimming test. Behav. Pharmacol. 4: 625-636, 1993.
110. 1A receptor antagonists. Eur. J. Pharmacol. 271: 537-541, 1994.
111. SHERMAN, A. D., SACQUITNE, J. L. AND PETTY, F.: Specificity of the learned helplessness model of depression. Pharmacol. Biochem. Behav. 16: 449-454, 1982.
112. 2 antagonists endowed with anxiolytic properties in rodents? Neurosci. Lett. 128: 4-8, 1991.
113. 1-adrenoceptor antagonism. J. Clin. Psychopharmacol. 15: 11S-18S, 1995.
114. 2 receptors and the wet-dog shakes they mediate, but not frontal cortical β-adrenoceptors. Eur. J. Pharmacol. 294: 721-726, 1995.
115. TANDA, G., CARBONI, E., FRAU, R. AND DI CHIARA, G.: Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepresaant potential? Psychopharmacology 115: 285-288, 1994.
116. 3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology 119: 15-19, 1995.
117. 4 dopamine receptors in fibroblast and dopaminergic cell lines. J. Pharmacol. Exp. Ther. 268: 495-502,1994.
118. 2 receptor binding sites. Drug Dev. Res. 24: 93-105, 1991.
119. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. ed. by R. J. Rodgers and S. J. Cooper, pp. 159-194, Wiley & Son Ltd, Chichester, 1991.
120. 2A in the rabbit. Naunyn-Schmiedeberg's Arch. Pharmacol. 348: 35-45, 1993.
121. 2-autoreceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 349: 25-33, 1994.
122. 3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J. Pharmacol. Exp. Ther. 271: 1558-1565, 1994.
123. N WIJNGAARDEN, I., TULP, M. TH. M. AND SOUDIJN, W.: The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188: 301-312, 1990.
124. WEINBERGEB, D. R.: Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44: 660-669, 1987.
125. WIELAND, S., FISCHETTE, C. T. AND LUCKI, I.: Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology 32: 561-573, 1993.
126. WILLNER, P.: Animal models as simulations of depression. Trends Pharmacol. Sci. 12: 131-137, 1991.
127. WILLNER, P.: Dopaminergic mechanisms in depression and mania. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 921-931, Raven Press Ltd., New York, 1995.
128. WONG D. T., BYMASTER F. P. AND ENGLEMAN, E. A.: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci. 57: 411-441, 1995.
129. 2 receptor-mediated behavior by continuous gepirone treatment. Life Sci. 49: 1777-1785, 1991.
130. ZACHARKO, R. M. AND ANISMAN, H.: Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci. Biobehav. Rev. 15: 391-405, 1991.
131. 7 receptors in guinea-pig brain. Br. J. Pharmacol. 115: 107-116, 1995.